Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Sintilimab in First-line Gastric Adenocarcinoma
NCT05795296Phase 2Unknown
- Sponsor
- Renji Hospital
- Start
- Dec 2022
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in gastric adenocarcinoma, adenocarcinoma of the esophagogastric junction (AEG), sponsored by Renji Hospital. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
gastric adenocarcinomaadenocarcinoma of the esophagogastric junction (AEG)
Beyond the preview
Go deeper on NCT05795296.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05795296.